Health Disparities in Cardiometabolic Disease Seen Within Racial Subgroups
By Elana Gotkine HealthDay Reporter
THURSDAY, Jan. 25, 2024 -- Health disparities are seen in the prevalence of cardiometabolic diseases by disaggregated racial and ethnic subgroups, according to research published in the Jan. 25 issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report.
Alain K. Koyama, Sc.D., from the CDC in Atlanta, and colleagues describe the prevalence of diagnosed cardiometabolic diseases among U.S. adults by disaggregated racial and ethnic subgroups using data from 3,970,904 respondents to the Behavioral Risk Factor Surveillance System from 2013 to 2021. The prevalence of diabetes, myocardial infarction, angina or coronary heart disease, and stroke was stratified by race and ethnicity.
The mean respondent age was 47.5 years, and more than half (51.4 percent) of the respondents were women. The researchers found that among disaggregated race and ethnicity subgroups, there was considerable variation seen in the prevalence of cardiometabolic diseases. Within the aggregated non-Hispanic Asian category, the prevalence of diabetes was 11.5 percent and ranged from 6.3 to 15.2 percent in the Vietnamese and Filipino subgroups, respectively. For the aggregated Hispanic or Latino category, the prevalence of angina or coronary heart disease was 3.8 percent and varied from 3.1 to 6.3 percent in the Cuban and Puerto Rican subgroups, respectively.
"Findings from this study illustrate pronounced differences in cardiometabolic disease prevalence among racial and ethnic subgroups, with the largest variation occurring in diabetes prevalence," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted January 2024
Read this next
Semaglutide Cuts Risk for Kidney Outcomes, Death in CKD With T2DM
FRIDAY, May 31, 2024 -- For patients with type 2 diabetes and chronic kidney disease, semaglutide reduces the risk for clinically important kidney outcomes and death from...
Demographic, Clinical, Financial Factors Tied to GLP-1 Agonist Discontinuation
WEDNESDAY, May 29, 2024 -- Specific demographic, clinical, and financial characteristics are associated with glucagon-like peptide 1 (GLP-1) receptor agonist discontinuation...
GLP-1 Receptor Agonist Dispensing Up From 2020 to 2023 for Teens, Young Adults
WEDNESDAY, May 22, 2024 -- For adolescents and young adults, glucagon-like peptide-1 receptor agonist (GLP-1 RA) dispensing increased from 2020 to 2023, according to a research...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.